Chemoprevention with antiestrogens: The beginning of the end for breast cancer. Daniel G. Miller lecture

Annals of the New York Academy of Sciences

Volumn 952, Issue , 2001, Pages 60-72

  Jordan, V Craig ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Antiestrogens; Breast cancer; Raloxifene; SERMs; Tamoxifen

Indexed keywords

ANTIESTROGEN; CLOMIFENE; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN; TAMOXIFEN CITRATE;

BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER PREVENTION; CHEMOPROPHYLAXIS; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONFERENCE PAPER; DRUG BLOOD LEVEL; DRUG RECEPTOR BINDING; ENDOMETRIUM CANCER; FEMALE; FEMALE FERTILITY; HIGH RISK PATIENT; HUMAN; ISCHEMIC HEART DISEASE; OVULATION; POSTMENOPAUSE OSTEOPOROSIS;

ACRONICTA LEPORINA;

EID: 0035686976     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2001.tb02728.x     Document Type: Conference Paper

References (95)

1. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 Randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women
2. Tamoxifen for early breast cancer: An overview of the randomised trials
3. Tamoxifen: A personal retrospective
4. Prevention of chemical carcinogenesis by vitamin A and its synthetic analogs (retinoids)
5. Approaches to prevention of epithelial cancer during the preneoplastic period
6. On the treatment of inoperable cases of carcinoma of the mamma: Suggestions for a new method of treatment with illustrative cases
7. On oophorectomy in cancer of the breast
8. Further investigations on the origin of tumors in mice II on the part played by internal secretion in the spontaneous development of tumors
9. An ovarian hormone: Preliminary report on its localization, extraction and partial purification and action in test animals
10. Hormonal pathogenesis of adenocarcinoma of the breast
11. Basic guides to the mechanism of estrogen action
12. A non-steroidal estrogen antagonist 1-(p-2-diethylaminoethoxyphenyl)-1-phenyl-2-p-methoxyphenylethanol
13. A new derivative of triphenylethylene: Effect on implantation and mode of action in rats
14. Antagonism of estrogen action with a new benzothiophene derived antiestrogen
15. The estrogen receptor from a tamoxifen stimulated MCF-7 tumor variant contains a point mutation in the ligand binding domain
16. A naturally occurring estrogen receptor mutation results in increased estrogenicity of a tamoxifen analog
17. Molecular basis of agonism and antagonism in the oestrogen receptor
18. The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen
19. Structure of the ligand-binding domain of oestrogen receptor beta in the presence of a partial agonist and a full antagonist
20. Tamoxifen: The herald of a new era of preventive therapeutics
21. Estrogen, selective estrogen receptor modulation, and coronary heart disease: Something or nothing
22. Development of antiestrogens and their use in breast cancer: Eighth Cain Memorial Award Lecture
23. Induction of ovulation with MRL-41 - Preliminary report
24. Official literature on new drugs: Clomiphene citrate (Clomid)
25. Contrasting endocrine activities of cis and trans isomers in a series of substituted triphenylethylenes
26. A new anti-oestrogenic agent in late breast cancer. An early clinical appraisal of ICI46474
27. The induction of ovulation by tamoxifen
28. Postcoital contraception
29. Antioestrogens. A review
30. Tamoxifen (ICI 46,474) and the human carcinoma 8S oestrogen receptor
31. Detection of the 8 S oestrogen-binding component in human uterine endometrium during the menstrual cycle
32. Antitumour activity of the antioestrogen ICI 46,474 (tamoxifen) in the dimethylbenzanthracene (DMBA)-induced rat mammary carcinoma model
33. Effect of tamoxifen (ICI 46,474) on initiation and growth of DMBA-induced rat mammary carcinomata
34. The effectiveness of long term tamoxifen treatment in a laboratory model for adjuvant hormone therapy of breast cancer
35. Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study
36. Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial
37. A monohydroxylated metabolite of tamoxifen with potent antioestrogenic activity
38. Evidence for the metabolic activation of non-steroidal antioestrogens: A study of structure-activity relationships
39. Structure-activity relationships of anti-oestrogens with regard to interaction with 17-beta-oestradiol in the mouse uterus and vagina
40. The pharmacology and clinical uses of tamoxifen
41. Effects of anti-estrogens on bone in castrated and intact female rats
42. Tamoxifen prevents the skeletal effects of ovarian hormone deficiency in rats
43. Tamoxifen inhibits osteoclast-mediated resorption of trabecular bone in ovarian hormone-deficient rats
44. Evaluation of the antitumour activity of the nonsteroidal antioestrogen monohydroxytamoxifen in the DMBA-induced rat mammary carcinoma model
45. Antitumor actions of keoxifene and tamoxifen in the N-nitrosomethylurea-induced rat mammary carcinoma model
46. Species-specific pharmacology of antiestrogens: Role of metabolism
47. Contrasting actions of tamoxifen on endometrial and breast tumor growth in the athymic mouse
48. A realistic clinical perspective of tamoxifen and endometrial carcinogenesis
49. Endometrial cancer in tamoxifen-treated breast cancer patients: Findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14
50. Differential antiestrogen action in the immature rat uterus: A comparison of hydroxylated antiestrogens with high affinity for the estrogen receptor
51. Inhibition of the uterotropic activity of estrogens and antiestrogens by the short acting antiestrogen LY117018
52. Effects of a new antiestrogen, keoxifene (LY156758), on growth of carcinogen-induced mammary tumors and on LH and prolactin levels
53. Phase II evaluation of Ly156758 in metastatic breast cancer
54. Raloxifene hydrochloride
55. Metabolites of tamoxifen in animals and man: Identification, pharmacology, and significance
56. Chemoprevention of mammary carcinogenesis in the rat: Combined use of raloxifene and 9-cis-retinoic acid
57. Raloxifene (LY139481 HCI) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats
58. Effects of tamoxifen on cardiovascular risk factors in postmenopausal women
59. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women
60. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: Results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators
61. The effect of raloxifene on risk of breast cancer in postmenopausal women: Results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation
62. Uterine effects of 3-year raloxifene therapy in postmenopausal women younger than age 60
63. Uterine effects of raloxifene in comparison with continuous-combined hormone replacement therapy in postmenopausal women
64. A 12-month comparative study of raloxifene, estrogen, and placebo on the postmenopausal endometrium
65. Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women
66. Raloxifene as a multifunctional medicine?
67. Possible mechanisms in the emergence of tamoxifen-resistant breast cancer
68. William L. McGuire Memorial Symposium. Drug resistance to tamoxifen during breast cancer therapy
69. Clinical significance of tamoxifen withdrawal response
70. Response after withdrawal of tamoxifen and progestogens in advanced breast cancer
71. Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors
72. Human breast cancer in the athymic nude mouse: Cytostatic effects of long-term antiestrogen therapy
73. Effect of estrogens and antiestrogens on growth of human breast cancer cells in athymic nude mice
74. Development of tamoxifen-stimulated growth of MCF-7 tumors in athymic mice after long-term antiestrogen administration
75. Inhibition of tamoxifen-stimulated growth of an MCF-7 tumor variant in athymic mice by novel steroidal antiestrogens
76. Estrogenic activity is increased for an antiestrogen by a natural mutation of the estrogen receptor
77. The key to the antiestrogenic mechanism of raloxifene is amino acid 351 (aspartate) in the estrogen receptor
78. Aspartate 351 of estrogen receptor alpha is not crucial for the antagonist activity of antiestrogens
79. An antiestrogen-responsive estrogen receptor-alpha mutant (D351Y) shows weak AF-2 activity in the presence of tamoxifen
80. Growth regulation of estrogen receptor-negative breast cancer cells transfected with complementary DNAs for estrogen receptor
81. Analysis of estrogen recept or function in vitro reveals three distinct classes of antiestrogens
82. Comparative analyses of mechanistic differences among antiestrogens
83. Paradoxical regulation of estrogendependent growth factor gene expression in estrogen receptor (ER)-negative human breast cancer cells stably expressing ER
84. An estrogen receptor model to describe the regulation of prolactin synthesis by antiestrogens in vitro
85. Differences between estrogen and antiestrogen-estrogen receptor complexes from human breast tumors identified with an antibody raised against the estrogen receptor
86. Structural requirements for the pharmacological activity of nonsteroidal antiestrogens in vitro
87. Sequence and expression of human estrogen receptor complementary DNA
88. Human oestrogen receptor cDNA: Sequence, expression and homology to v-erb-A
89. The oestrogen-like effect of 4-hydroxytamoxifen on induction of transforming growth factor alpha mRNA in MDA-MB-231 breast cancer cells stably expressing the oestrogen receptor
90. Selective oestrogen receptor modulation: Molecular pharmacology for the millennium
91. Allosteric silencing of activating function 1 in the 4-hydroxytamoxifen estrogen receptor complex is induced by substituting glycine for aspartate at amino acid 351
92. Molecular mechanism of action at estrogen receptor alpha of a new clinically relevant antiestrogen (GW7604) related to tamoxifen
93. Peptide antagonists of the human estrogen receptor
94. Silencing and reactivation of the selective estrogen receptor modulator (SERM)-ER alpha complex
95. Designer estrogens